Skip to main content

Posters

November 22, 2019
BACKGROUND: In the 12-week ARM-TD and AIM-TD studies of patients with tardive dyskinesia (TD), the percentage of patients achieving ≥50% and ≥70% responses (i.e. reductions from baseline in Abnormal Involuntary Movement Scale (AIMS) scores) was higher in the deutetrabenazine-treated group compared…
November 22, 2019
This post hoc analysis evaluates whether improvement in hallucinations and delusions during pimavanserin (PIM) treatment among Alzheimer’s dementia (AD) patients with psychosis leads to improvement in symptoms of agitation and aggression. This was a 12 week, randomized, double-blind, placebo-…
November 22, 2019
Introduction: RBP-7000 (PERSERIS™) is a once-monthly, subcutaneous, extended-release risperidone formulation that is approved for treating schizophrenia in adults and is designed to deliver clinically relevant plasma concentrations on the first day of dosing (with no loading or supplemental dosing).
November 22, 2019
Introduction: Evaluation of patients with serious mental illness (SMI) relies largely on patient or caregiver self-reported disease symptoms. New technologies (e.g., mobile-based interventions, computerized cognitive remediation, digital medication adherence monitoring) are being developed to…
November 22, 2019
Background: SEP-363856 is a novel trace amine associated receptor-1 (TAAR1)/5-HT1A agonist with no dopamine-D2/5-HT2A antagonist activity which has shown efficacy in animal models of psychosis. The aim of this study was to evaluate the efficacy and safety of SEP-363856 for schizophrenia.
November 22, 2019
BACKGROUND: Deutetrabenazine, a novel vesicular monoamine transporter 2 (VMAT2) inhibitor, is approved by the FDA for treatment of tardive dyskinesia (TD) in adults. Dopamine-receptor antagonists (DRAs) are associated with worsening of metabolic parameters, including weight gain, hyperlipidemia,…
November 22, 2019
Background: Valbenazine is approved for the treatment of tardive dyskinesia (TD), a persistent and disabling movement disorder associated with prolonged antipsychotic exposure. Data from KINECT 3 were analyzed post hoc to evaluate changes in TD (based on Abnormal Involuntary Movement Scale [AIMS])…
November 22, 2019
Background: We assessed effects contributing to weight gain during long-term treatment with brexpiprazole.
November 22, 2019
Introduction: Assessing factors that determine patients’ preferences for long-acting injectable (LAI) or oral antipsychotics could help reduce potential barriers to LAI use in schizophrenia.
November 22, 2019
Background: This study examined experiences of patients living with schizophrenia with a history of oral antipsychotic medication (OAM) use.
Back to Top